Journal of Neurology

, Volume 251, Issue 11, pp 1370–1374 | Cite as

A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease

  • Hilary L. Tyne
  • Jan Parsons
  • Ann Sinnott
  • Susan H. Fox
  • Nicholas A. Fletcher
  • Malcolm J. Steiger



Apomorphine is a potent dopamine agonist useful in the treatment of Parkinson’s disease patients with disabling motor fluctuations and ‘off’ periods, not responding to oral medication. It can also be of benefit in reducing dyskinesia by providing more constant dopaminergic stimulation and permitting lower levodopa dosage. However, there is a paucity of information on long-term benefits of apomorphine, including no large-scale phase III trial. We have examined our experience of apomorphine over the last 10 years, to assess indications, pattern of use, efficacy, and side effect profile.


All patients requiring apomorphine were identified through the Parkinson’s disease Nurse Specialist’s records. An audit form was produced so that the same information was gathered from all case-notes.


There were 107 patients (61 males and 46 females). Mean age of disease onset was 50.9 years, SD±9.3 (range 29–78). The mean duration of disease at start of apomorphine treatment was 10 years (SD±4.8, range2–29). The most common indications for apomorphine were severe unpredictable ‘off’ periods (75.7 %), motor fluctuations (18.7 %) and dyskinesia (5.6 %). Most patients (63.6 %) used both intermittent subcutaneous injections and infusion via pump; 25.2% were on intermittent injection, and 11.2 % infusion alone. Mean dose per injection was 3.7mg. Mean infusion dose 69.8mg, running over a mean of 13.5 hours. The mean duration of intermittent apomorphine use was 48.2 months. The mean duration of infusion was 25.1 months. Complications included skin problems in 16 patients, 2 had symptomatic hypotension, 2 worsening confusion, 1 new confusion and 5 new hallucinations (after sometime on apomorphine). Sixteen patients have stopped using apomorphine completely. Thirteen have stopped the pump, but continue on intermittent injections.


Subcutaneous apomorphine is easy for patients to use, is well tolerated and has a low incidence of side effects, especially confusion.

Key words

Parkinson’s disease apomorphine motor fluctuations 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anden NE, Rubenson A, Fuxe K, et al. (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharmac Pharmacol 19:627–629Google Scholar
  2. 2.
    Cantello R, Gilli M, Riccio A, Bergamasco B (1986) Mood changes associated with “end of dose deterioration” in Parkinson’s disease: a controlled study. J Neurol Neurosurg Psychiatry 49:1182–1190PubMedGoogle Scholar
  3. 3.
    Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64:573–576PubMedGoogle Scholar
  4. 4.
    Corsini GU, Del Zompo M, Gessa GL, Mangoni A (1979) Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1:954–956PubMedGoogle Scholar
  5. 5.
    Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M (1976) Treatment of Parkinson’s disease with aporphines. Possible role of growth hormone. N Engl J Med 294(11):567–572PubMedGoogle Scholar
  6. 6.
    Dewey Jr RB, Hutton JT, LeWitt PA, Factor SA (2001) A randomized double-blind, placebo controlled trial of subcutaneously injected apomorphine for Parkinsonian off states. Arch Neurol 58:1385–1392CrossRefPubMedGoogle Scholar
  7. 7.
    Ernst AM (1967) Mode of action of apomorphine and dexamphetamine in gnawing compulsion in rats. Psychopharmacologia 10(4):316–323CrossRefPubMedGoogle Scholar
  8. 8.
    Frankel JP, Lees AJ, Kempster PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 53(2):96–101PubMedGoogle Scholar
  9. 9.
    Hardie RJ, Lees AJ, Stern GM (1984) On-Off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 107:487–506PubMedGoogle Scholar
  10. 10.
    Kumar R, Lozano A, Kim YJ, et al. (1998) Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson’s disease. Neurology 51:850–855PubMedGoogle Scholar
  11. 11.
    Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 17:1235–1241CrossRefPubMedGoogle Scholar
  12. 12.
    Marsden CD, Parkes JD (1976) “On-Off” effects in patients with Parkinson’s disease on chronic levodopa therapy Lancet 1:292–296PubMedGoogle Scholar
  13. 13.
    Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet i:345–349Google Scholar
  14. 14.
    Quinn NP, Koller WC, Lang AE, Marsden CD (1986) Painful Parkinson’s disease. Lancet 1:1366–1369PubMedGoogle Scholar
  15. 15.
    Schwab RS, Amador LV, Lettvin JY (1951) Apomorphine in Parkinson’s disease. Transf Am Neurol Assoc 76:251–253Google Scholar
  16. 16.
    Shaw KM, Lees AJ, Stern GM (1980) The impact of treatment with levodopa on Parkinson’s disease. QJM 49:283–293PubMedGoogle Scholar
  17. 17.
    Steiger MJ, Quinn NP, Marsden CD (1992) The clinical use of apomorphine in Parkinson’s disease. J Neurol 239:389–393PubMedGoogle Scholar
  18. 18.
    Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1:403–406PubMedGoogle Scholar
  19. 19.
    Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson’s disease: long-term results. Neurol Sci 22:93–94PubMedGoogle Scholar
  20. 20.
    Varma TR, Fox SH, Eldridge PR, et al. (2003) Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson’s disease patients previously reliant on apomorphine. J Neurol Neurosurg Psychiatry 74:170–174PubMedGoogle Scholar
  21. 21.
    Weil E (1884) De l’apomorphine dans certain troubles nerveux. Lyon Med 48:411–419Google Scholar

Copyright information

© Steinkopff Verlag 2004

Authors and Affiliations

  • Hilary L. Tyne
    • 1
  • Jan Parsons
    • 2
  • Ann Sinnott
    • 2
  • Susan H. Fox
    • 2
  • Nicholas A. Fletcher
    • 2
  • Malcolm J. Steiger
    • 2
  1. 1.The University of LiverpoolUK
  2. 2.The Walton Centre for Neurology and NeurosurgeryLiverpool L9 7LJUK

Personalised recommendations